Progressive Supranuclear Palsy (PSP) is also known as Steele-Richardson-Olszewski syndrome, is an uncommon brain disorder that affects movement, control of walking and balance, speech, swallowing, vision, mood and behaviour, and thinking.
Progressive Supranuclear Palsy (PSP) is a rare progressive condition, which can cause issues with balance, movement, vision, speech, and swallowing.
The condition has been linked to alternations in specific genes, but these genetic faults are not inherited and the risk to other family members with PSP, is very low.
Although PSP is not fatal, symptoms do continue to worsen, and it can not be cured. Complications that result from worsening symptoms, such as pneumonia—from breathing in food particles while choking during eating—can be life-threatening.
The only proven risk factor for PSP is age. Typically, the condition affects people around the age of 60 and is virtually unknown in people under the age of 40.
Progressive Supranuclear Palsy Epidemiological Segmentation
The Epidemiological Segmentation of Progressive Supranuclear Palsy in 7MM from 2017 to 2030 is segmented as:-
• Total Prevalent cases of Progressive Supranuclear Palsy
• Gender-specific Prevalent Cases of PSP
• Phenotype associated with PSP
• Comorbidities associated with PSP
Progressive Supranuclear Palsy Epidemiology
• Total prevalent cases of PSP in 7 MM in 2017 were 98,498
• The prevalence of PSP in the United States in 2017 was 20,161
• Males are affected more as compared to females
The therapeutic market of Progressive Supranuclear Palsy in 7MM in 2017 was USD 10.54 million.
Progressive Supranuclear Palsy Emerging Drugs
The Emerging drugs of the Progressive Supranuclear Palsy market are
And many others.
Progressive Supranuclear Palsy Key Players
The key players in the Progressive Supranuclear Palsy market are
• UCB Biopharma
• Asceneuron Therapeutics
• TauRx Pharmaceuticals
And many others.